Moffitt logo

Clinical Trials Search

Clinical Trial 20943

Cancer Type: Genitourinary
Study Type: Treatment
NCT#: NCT04863885

Phase: Phase I/II
Prinicipal Investigator: Rohit Jain

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Summary

The purpose of this study is to see how well the study drugs called Ipilimumab plus Nivolumab (IPI-NIVO) work when added to another study drug called Sacituzumab Govitecan for people who have metastatic bladder cancer.

Objective

Phase I: Feasibility and tolerability of IPI-NIVO combined with sacituzumab as first-line therapy for cisplatin-ineligible patients with metastatic urothelial carcinoma Phase II: To evaluate measurable disease overall response rate (ORR) of IPI-NIVO combined with sacituzumab as first-line therapy for cisplatin-ineligible patients with metastatic urothelial carcinoma. Phase I: 1. Measurable disease overall response rate (ORR) 2. Duration of response (DOR) 3. Progression-free survival (PFS) 4. Overall Survival (OS). Phase II 1) To evaluate progression-free survival (PFS). 2) Duration of response (DOR) 3) To evaluate Overall Survival (OS).4) To evaluate toxicities

Treatments

Therapies

Medications

BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Sacituzumab Govitecan (); Yervoy (Ipilimumab)

Inclusion Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Able to understand and give written informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Participants with histologically documented locally advanced or metastatic urothelial carcinoma. Upper and lower tract tumors are permitted and mixed histologies are permitted if urothelial carcinoma is the predominant histology (>/= 50%).
  • Ineligibility for cisplatin-based chemotherapy, defined by any of the following: (a) Creatinine clearance (CL) 1 hearing loss (c) CTCAE v5.0 Grade > 1 neuropathy (d) NYHA Class > II cardiac dysfunction
  • Adequate organ function laboratory values as defined per protocol
  • Have measurable disease by CT or MRI as per RECIST 1.1 criteria. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre- menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: (a) Women 1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  • Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy. Female participants if sexually active must agree to use dual methods of contraception during the study and for a minimum period of 5 months after the last dose of study drug.
  • Other criteria may apply

  • Exclusion Criteria

    Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of trial treatment.
  • Prior chemotherapy for metastatic urothelial carcinoma at any time in the patient's medical history.
  • Small-cell carcinoma component
  • Prior chemotherapy for localized urothelial carcinoma completed within 12 months before registration. Has received anti-PD-1/PD-L1 therapy previously, except if used in earlier stage urothelial carcinoma such as non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancer (MIBC) as neoadjuvant or adjuvant therapy and completed >3 months prior to registration.
  • Prior therapy with sacituzumab govitecan, irinotecan, or any topoisomerase I-containing regimen or antibody-drug conjugate
  • Received radiation therapy for bone metastasis > Requires concomitant medication interfering with ABCA1 transporter or UGT1A1
  • Participants with Gilbert's disease.
  • An active second malignancy. Note: Participants with a history of malignancy that has been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or subjects with surgically cured tumors with low risk of recurrence are allowed to- enroll.
  • Known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and all neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids greater than 20 mg of prednisone daily for brain metastases (or the equivalent) for at least 7 days prior to trial treatment. All participants with carcinomatous meningitis are excluded regardless of clinical stability.
  • Active cardiac disease as defined in protocol.
  • Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) and participants with a history of bowel obstruction.
  • Prior history of clinically significant bleeding, intestinal obstruction, or GI perforation within 6 months of enrollment.
  • Must be at least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids ≤10 mg prednisone or equivalent daily are permitted for reasons outside of CNS disease provided the dose is stable for 4 weeks).
  • Active infection requiring systemic treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study
  • Active autoimmune disease requiring systemic treatment with steroids or other immunosuppressive agent or any condition that in the Investigator's judgment precludes treatment with IPI-NIVO
  • Received a live vaccine within 30 days prior to the first dose of study drug(s)
  • History or evidence of interstitial lung disease (ILD) or non-infectious pneumonitis
  • Known history of HIV-1/2 with uncontrolled viral load and on medications that may interfere with SN-38 metabolism.
  • Known active Hepatitis B or Hepatitis C (In subjects with a history of HBV, hepatitis B core antibody (HBcAb) testing is required and if positive, then HB DNA testing will be performed and if positive the patient will be excluded).
  • Other criteria apply

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.